News and blogs
175 results found.
Combination treatment improves treatment for people with relapsed myeloma
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn’t responded to previous treatment, to liv
New study strengthens evidence for new CAR T-cell treatment for aggressive blood cancer
The scientists tested a new treatment called BE-CAR7, which uses gene editing to change donor immune cells so they can find and destroy cancer.
New trial shows early signs that ‘off-the-shelf’ CAR T-cell therapy could transform treatment of myeloma
A new trial shows early signs that ‘off-the-shelf’ CAR T-cell therapy could transform treatment of myeloma
Blood Cancer UK funded trial shows survival gain, as experts say drug could be repurposed as new treatment standard for rare blood cancer
A new UK trial has found that an oral treatment called ASTX727, could help people with certain rare blood cancers to live longer.
New treatment for aggressive blood cancer now approved on the NHS in England
People living with diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood cancer, who don’t respond to treatment or whose cancer has come back, will soon have access to a new treatment on the NHS.
Funding bold ideas in blood cancer research
We’re delighted to be investing in 12 new research projects to allow researchers to test original approaches and generate the first results to unlock major funding.
Belfast researchers backed to boost defence against blood cancer
Researchers received £20,000 of funding from Blood Cancer UK to investigate how they could develop new treatments that boost the immune system.
Survival in people with myeloma nearly doubles since 2005
People diagnosed the blood cancer - myeloma - are now living nearly twice as long on average as they were in 2005.
Acceleration through strategy and science: highlights from our 2025 Research Symposium
In July, 120 leading blood cancer researchers and partners gathered for Blood Cancer UK’s Research Symposium at the Royal College of Physicians. With 14 presentations on 7 different blood cancers, researchers shared bold ideas and their latest progress a
We've come so far but we're not done yet: accelerating research progress
Blood Cancer UK are accelerating progress through research and will invest £70m in the next five years.
Manchester researcher awarded £300k as Blood Cancer UK launches £70 million strategy
A researcher at the University of Manchester has been awarded a 3-year research fellowship as Blood Cancer UK launches a bold new strategy to invest £70 million in life-saving research over the next five years.
Cambridge researchers awarded £700k as charity launches £70 million strategy to beat blood cancer
Researchers at the University of Cambridge have been awarded two research fellowships as Blood Cancer UK launches a bold new strategy to invest £70 million in life-saving research over the next five years.
Harnessing the power of T-cells in stem cell transplants
Stem cell transplants can be a life-saving treatment for people with myeloma, a type of blood cancer that can be treated but currently has no cure. Dr Dimeloe tells us how she is harnessing the power of T-cells in her research.
Patients on NHS are first in the world to access new myeloma drug
Around 3,600 patients across England and Wales every year will now be eligible for this treatment combination.
How are clinical trials going to help beat blood cancer in a generation?
On clinical trials day we want to celebrate the vital role clinical trials play in improving survival for people with blood cancer. Read more about how we are supporting clinical trials.
Bone marrow test that spots residual leukaemia in trial could help improve survival
Researchers at King’s College London have found a test that detects traces of disease in the bone marrow of people with acute myeloid leukaemia (AML), a type of blood cancer. The procedure identified signs of AML returning in blood cancer patients before
New research shows a common diabetes drug may prevent aggressive leukaemia
Metformin appears highly specific to people with a certain DNA change at high risk of developing AML rather than being a generic treatment. This specificity makes it especially compelling as a targeted prevention strategy.
A new era of funding for blood cancer research
We’re thrilled to introduce the Transformational Research Awards. A major step forward in our mission to fund pioneering research to transform blood cancer treatment for all ages.
Blood cancer survivor is ‘luckiest man alive’ as treatment helps gain approval for use on NHS
England’s drug regulators have recommended two new treatments for blood cancer for use on the NHS.
AI: it’s not all “robot uprisings” - A true force for good in the healthcare space
Read more how blood cancer researcher Professor Daniel Royston is using AI to help improve the diagnosis and treatment of blood cancer.
